assays using a highly selected patient population. The study was performed for a German population where, as in much of Europe, ergocalciferol (vitamin D 2 ) supplementation is not in widespread use and as highlighted by Roth, the effect of 25-hydroxyvitamin D 2 on assay results was not investigated. Thus, there is no confirmation in this study that the German population did not have circulating 25-hydroxyvitamin D 2 from sources other than pharmaceutical supplementation.
Given the dramatic increase in vitamin D requests in recent years, 2 the performance of fully automated assays in the Roth study, such as the Roche Vitamin D 3 (25-OH) electrochemiluminescence immunoassay (ECLIA), will be of interest to many laboratories. Recently, we evaluated the same ECLIA on a Roche E170 analyser for 54 patient samples from a north London population and 12 samples from the international vitamin D external quality assessment scheme (DEQAS). ECLIA results were compared with high-performance liquid chromatography -mass spectrometry (LC-MS), which resolves both 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 , and was our reference method.
We agree with Roth et al. in that the ECLIA results are highly reproducible, with inter-and intra-assay CVs (4.9-5.6% and 2.2 -2.9%, respectively, determined using Roche PreciControl Bone Quality Control samples) agreeing well with manufacturer values and showing a low bias (mean bias: þ4.4 nmol/L, limits of agreement: -52.4 to þ86.7 nmol/L, as determined by Bland-Altman analysis) against the LC-MS 25-hydroxyvitamin D 3 values. While less bias was observed against the DEQAS ALTM (constant bias of þ17.03% and a proportional bias of þ0.81% using Deming regression) than reported for other automated assays, 3 none of these samples had measurable 25-hydroxyvitamin D 2 concentrations. Close to the lower limit of detection (10 nmol/L), ECLIA overestimated 25-hydroxyvitamin D 3 in all analyses performed, reducing the number of acutely deficient (,12.5 nmol/L) 4 subjects detected.
The concentrations for our patient samples (mean + standard deviation) of 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 and total 25-hydroxyvitamin D, as determined by LC-MS, were 2.5 + 51.6 nmol/L, 62.5 + 41.4 nmol/L and 65.6 + 62.1 nmol/L, respectively. Of the 54 patients examined, nine were found to have appreciable 25-hydroxyvitamin D 2 concentrations (.20 nmol/L). Five of these nine subjects were 25-hydroxyvitamin D sufficient (.50 nmol/L) 4 yet were misdiagnosed as insufficient (,50 nmol/L) by the ECLIA. One patient, falsely diagnosed as insufficient had a total 25-hydroxyvitamin D concentration of 334 nmol/L, yet was measured as 14 nmol/L by ECLIA. Given the observation that approximately 17% of our study population had significant 25-hydroxyvitamin D 2 concentrations, we suggest that inability to detect 25-hydroxyvitamin D 2 must still be considered a major drawback of 25-hydroxyvitamin D 3 assays for routine testing. 3 While the recent study by Kimball and Veith suggests that the effects of a high vitamin D concentration may vary between individuals, 5 it is possible that low 25-hydroxyvitamin D 3 measurements might accompany sufficient total vitamin D concentrations or indeed hypercalcaemia due to 25-hydroxyvitamin D 2 toxicity. This may result in inappropriate supplementation, inaccurate monitoring and potential misdiagnosis of clinical hypercalcaemia. Studies have suggested that the reporting of individual values for 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 can lead to confusion and misdiagnoses among health-care practitioners, 6 a situation which may be compounded if the form of vitamin D supplementation for a given patient is not known.
Further, since there is a lack of clarity as to the bioequivalence, or otherwise, of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 , 7 -9 an assay that measures either metabolite alone would appear to be of limited use. It is suggested that any 25-hydroxyvitamin D assay in routine clinical use must accurately detect both 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 on an equimolar basis. Response to Costelloe et al.
In their Letter to the Editor, Costelloe et al. draw attention to the fact that the Roche electrochemiluminescence immunoassay (ECLIA) 25-hydroxyvitamin D assay is highly reproducible with a low bias against LC-MS and therefore suitable for high-throughput measurement, but with the major drawback of not detecting 25-hydroxyvitamin D 2. The predominant natural source of vitamin D in humans is vitamin D 3 and nutritional intake of vitamin D 2 does not contribute significantly to the human vitamin D reservoir. 1 -3 In a recent analysis of 153 randomly selected samples with total 25-hydroxyvitamin D concentration ,60 nmol/L, we found only six to have detectable 25-hydroxyvitamin D 2 as determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (unpublished observations). These concentrations were negligible (,8 nmol/L), confirming the data on 291 cases, which were representative for the German population, from our paper. 4 There is no vitamin D fortification of dietary products in Germany and in the USA fortification is primarily with vitamin D 3 , in quantities which are too low to have a substantial beneficial effect. 5 Furthermore, in Germany, vitamin D as a supplement is available over-the-counter or the internet only in the form of vitamin D 3 and in the USA, as low content multivitamin (vitamin D 2 or D 3 ) or higher content preparations as vitamin D 3 . 5 Unlike the situation in the UK and the USA, vitamin D 2 as a prescription supplement is not available in Germany. As a result we can assume that vitamin D 2 supplementation or prescription plays no role in Germany. 
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